LOS ANGELES, March 7, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice President of Business Development and Investor Relations, will present a corporate update at the 29th Annual ROTH Conference on Tuesday, March 14th at 5:30 p.m. Pacific Time at the Ritz-Carlton in Dana Point, California.
A live and archived webcast of the presentation will be available at http://wsw.com/webcast/roth31/cytr.
About the 29th Annual ROTH Conference
With close to 500 participating companies and over 4,000 attendees, the ROTH Conference will feature presentations from hundreds of public and private companies in a variety of sectors including healthcare. This gathering of institutional investors, private equity investors, VCs, company executives and service providers has become a must attend event for anyone working in the small and mid-cap space.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is also expanding its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome, timing and results of CytRx's clinical testing of aldoxorubicin and preclinical testing of its LADR™ linker technology platform and the other risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx's most recent annual report. These risks could cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:CytRx CorporationDavid J. HaenVice President, Business Development and Investor Relations(310) 826-5648, ext [email protected]
Investor Relations Contact:Argot PartnersMichelle Carroll(212) [email protected]
Advertisement
A live and archived webcast of the presentation will be available at http://wsw.com/webcast/roth31/cytr.
About the 29th Annual ROTH Conference
Advertisement
With close to 500 participating companies and over 4,000 attendees, the ROTH Conference will feature presentations from hundreds of public and private companies in a variety of sectors including healthcare. This gathering of institutional investors, private equity investors, VCs, company executives and service providers has become a must attend event for anyone working in the small and mid-cap space.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is also expanding its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome, timing and results of CytRx's clinical testing of aldoxorubicin and preclinical testing of its LADR™ linker technology platform and the other risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx's most recent annual report. These risks could cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:CytRx CorporationDavid J. HaenVice President, Business Development and Investor Relations(310) 826-5648, ext [email protected]
Investor Relations Contact:Argot PartnersMichelle Carroll(212) [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cytrx-to-present-at-the-29th-annual-roth-conference-300419014.html
SOURCE CytRx Corporation
